Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H13N |
Molecular Weight | 159.2276 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(CC#C)CC1=CC=CC=C1
InChI
InChIKey=DPWPWRLQFGFJFI-UHFFFAOYSA-N
InChI=1S/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3
Molecular Formula | C11H13N |
Molecular Weight | 159.2276 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2039 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9564606 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Eutonyl Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
75 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/490428/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PARGYLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
272 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/490428/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PARGYLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/490428/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PARGYLINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/8114614/ Page: 7.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8114614/ Page: 7.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8114614/ Page: 7.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/11306107/ Page: 10.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11306107/ Page: 10.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Treatment with clorgyline and pargyline differentially decreases clonidine-induced hypotension and bradycardia. | 1984 Sep |
|
[Effects of pentoxifylline on 5-hydroxytryptamine in the mouse brain]. | 1985 Nov |
|
Chronic but not acute treatment with antidepressants enhances the electroconvulsive seizure response in rats. | 1985 Oct |
|
Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. | 1987 Sep |
|
The MAO-B inhibitor deprenyl, but not the MAO-A inhibitor clorgyline, potentiates the neurotoxicity of p-chloroamphetamine. | 1994 Jul 11 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3208065
Curator's Comment: The two molecular forms of monoamine oxidase (MAO), MAO-A and MAO-B, were determined quantitatively in discrete regions of the human brain at autopsy, and in cerebral microvessels, choroid plexus and liver samples from the same subjects. MAO was assessed by specific[3H] pargyline binding, which is stoichiometric and irreversible, and by measuring the rate of oxidation of several MAO substrates. Basal ganglia structures (caudate, putamen, globus pallidus and substantia nigra) and hippocampus had about twice the levels of MAO that were present in the cerebral cortex and cerebellum. Cerebral microvessels, which constitute the blood-brain barrier, had minimal MAO, while the choroid plexus, which constitutes the blood-cerebrospinal fluid barrier, and the liver had higher MAO levels than any brain region. The vast majority of MAO (80-95%) in these tissues was of the B type, except in microvessels, where total MAO activity was low. Specific [3H]pargyline binding correlated well with the oxidation rates for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and benzylamine in all tissues. Both specific [3H]pargyline binding and the rate of oxidation of MAO substrates increased with age.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:11:57 GMT 2023
by
admin
on
Fri Dec 15 16:11:57 GMT 2023
|
Record UNII |
9MV14S8G3E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C02LL01
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
||
|
NCI_THESAURUS |
C270
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
||
|
WHO-VATC |
QC02LL01
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
||
|
NCI_THESAURUS |
C667
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
||
|
WHO-VATC |
QC02KC01
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
||
|
WHO-ATC |
C02KC01
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB01626
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
7262
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
2065
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
DTXSID3023423
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
555-57-7
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
100000082797
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
9MV14S8G3E
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
1350
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
D010293
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
209-101-6
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
m8412
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | Merck Index | ||
|
4688
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
7930
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | RxNorm | ||
|
C66322
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
SUB09626MIG
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
PARGYLINE
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY | |||
|
CHEMBL673
Created by
admin on Fri Dec 15 16:11:57 GMT 2023 , Edited by admin on Fri Dec 15 16:11:57 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |